What Glepaglutide is
Glepaglutide is an investigational GLP-2 analog in the intestinal-failure and gut-adaptation drug-development pipeline.
Glepaglutide is grouped under Approved / Clinical / Fat Loss + GLP-1s on PeptideFactCheck because it broadens the site beyond gym peptides by showing the real clinical peptide pipeline in GI medicine.
The useful starting point is to separate the molecule itself from the internet story around it. It broadens the site beyond gym peptides by showing the real clinical peptide pipeline in GI medicine.
Why people keep looking it up
It broadens the site beyond gym peptides by showing the real clinical peptide pipeline in GI medicine.
Glepaglutide is an investigational GLP-2 analog in the intestinal-failure and gut-adaptation drug-development pipeline.
Glepaglutide tends to stay in the conversation because it touches a familiar public theme: glp-2 analog, intestinal adaptation, and gut support. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Clinical-stage human development signal without an approved label.
Human clinical work exists, but the compound remains investigational in the current record.
Mechanism follows GLP-2 biology and intestinal-support signaling.
Why this page carries the current tier: Clinical-stage human development signal without an approved label.
The current seed trail for Glepaglutide is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
It should be discussed as a clinical-stage GI peptide, not as a generic wellness product.
Glepaglutide remains investigational in this seed set.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Glepaglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Glepaglutide is CID 146170995. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 146170995
- Formula
- C197H325N53O55
- Molecular weight
- 4316
- InChIKey
- DOAUQKRTILFGHV-PDCMDPCFSA-N
Matched synonyms include ZP1848, Glepaglutide (USAN), ZP-1848, GLEPAGLUTIDE [USAN], glepaglutida, glepaglutidum, RefChem:143328, GLEPAGLUTIDE [INN].
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Glepaglutide returns 9 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Glepaglutide returns 35 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.